Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis (Limit-JIA)
NCT03841357Phase 3Completed
- Sponsor
- Duke University
- Start
- Oct 2019
- Primary completion
- Jan 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abatacept in juvenile idiopathic arthritis (JIA) (4 arms), sponsored by Duke University. Primary endpoints: Composite of All Primary Endpoints at 410 days, Number of Participants With Polyarthritis at 592 days and 2 more. Started Oct 2019; status: completed.
02
Drugs
abatacept
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT03841357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841357.